Introgen is applying its adenoviral vector technology to the development of personalized therapeutic cancer vaccines. For a personalized vaccine, blood is obtained from a cancer patient and used as a source of dendritic cells, a type of cell that plays a critical role in activating T-cells to attack cancerous or virally infected cells. An adenoviral vector is then used to deliver a tumor suppressor encoding a cancer-related protein to the purified dendritic cells. When these modified dendritic cells are returned to the patient's body, they activate the patient's T-cells to seek out and destroy cancer cells that express the selected cancer protein.
Introgen's cancer vaccine technology platform is a promising approach to developing novel cancer therapies:
- The vaccines are personalized to work with a patient's own immune system
- The adenoviral vector system can be used to deliver a wide variety of cancer-related tumor suppressors
- The vaccines harness the power of the patient's immune system to destroy cancer cells while having minimal impact on healthy tissue
Introgen's product development candidate INGN 225, currently in Phase 1-2 clinical trials, utilizes the Company's cancer vaccine technology platform.
